Cytokinetics, Incorporated (CYTK) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 74.11 |
| Open | 73.23 |
| Day High | 75 |
| Day Low | 73.23 |
| 52-Week High | 88.31 |
| 52-Week Low | 47.22 |
| Volume | 775,096.99 |
| Average Volume | 2.06M |
| Market Cap | 9.19B |
| PE | -10.23 |
| EPS | -7.22 |
| Moving Average 50 Days | 78.79 |
| Moving Average 200 Days | 69.86 |
| Change | -0.27 |
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
GlobeNewswire Inc.
Feb 17, 2026 12:30 PM GMT
European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Euro
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
GlobeNewswire Inc.
Feb 12, 2026 9:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement,
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
GlobeNewswire Inc.
Feb 09, 2026 12:30 PM GMT
Grants Awarded to Two Patient Advocacy Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its eig